VET3-TGI yields 71% response rate in refractory cutaneous malignancies
Phase 1/1b STEALTH-001 data show a 71% response rate in seven checkpoint-refractory cutaneous cancer patients, with no dose-limiting toxicities and responses in uninjected lesions.